ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) - Morgensztern, D; Ong, TJ; Dols, MC; Aix, SP; Postmus, PE; Lewanski, C; Bennouna, J; Fischer, JR; Vidal, OJ; Stewart, DJ; Fasola, G; Ardizoni, A; et al. (Oxford University Press, 2017)